CBAY Stock Overview
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
CymaBay Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$32.48 |
| 52 Week High | US$32.50 |
| 52 Week Low | US$7.26 |
| Beta | 0.32 |
| 1 Month Change | 0.87% |
| 3 Month Change | 40.67% |
| 1 Year Change | 262.91% |
| 3 Year Change | 607.63% |
| 5 Year Change | 147.94% |
| Change since IPO | 260.89% |
Recent News & Updates
Recent updates
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%
Feb 15
Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher
Dec 22CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?
Dec 28CymaBay Therapeutics GAAP EPS of -$0.31 misses by $0.01
Aug 11Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?
Jul 13CymaBay: Long-Term Potential Based On Prior PBC Trial Results
Jun 27Is CymaBay Therapeutics (NASDAQ:CBAY) Using Debt In A Risky Way?
Mar 17Why I've Taken A 'Starter' Position In CymaBay Therapeutics
Jan 20Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?
Dec 03We Think CymaBay Therapeutics (NASDAQ:CBAY) Can Afford To Drive Business Growth
May 15We're Hopeful That CymaBay Therapeutics (NASDAQ:CBAY) Will Use Its Cash Wisely
Jan 29
CymaBay Therapeutics (CBAY) Presents At AASLD 2020 Conference- Slideshow
Nov 17CymaBay Is Clawing Back, Now We Just Need Pipeline Conversion
Nov 08CymaBay Therapeutics EPS in-line
Nov 05Shareholder Returns
| CBAY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.03% | -1.5% | -2.4% |
| 1Y | 262.9% | 7.9% | 23.4% |
Return vs Industry: CBAY exceeded the US Pharmaceuticals industry which returned 25.3% over the past year.
Return vs Market: CBAY exceeded the US Market which returned 31.2% over the past year.
Price Volatility
| CBAY volatility | |
|---|---|
| CBAY Average Weekly Movement | 8.2% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CBAY's share price has been volatile over the past 3 months.
Volatility Over Time: CBAY's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 101 | Sujal Shah | www.cymabay.com |
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes.
CymaBay Therapeutics, Inc. Fundamentals Summary
| CBAY fundamental statistics | |
|---|---|
| Market cap | US$3.73b |
| Earnings (TTM) | -US$105.37m |
| Revenue (TTM) | US$31.07m |
120.0x
P/S Ratio-35.4x
P/E RatioIs CBAY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBAY income statement (TTM) | |
|---|---|
| Revenue | US$31.07m |
| Cost of Revenue | US$80.80m |
| Gross Profit | -US$49.73m |
| Other Expenses | US$55.64m |
| Earnings | -US$105.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | -160.03% |
| Net Profit Margin | -339.10% |
| Debt/Equity Ratio | 37.4% |
How did CBAY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/21 12:27 |
| End of Day Share Price | 2024/03/21 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CymaBay Therapeutics, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Julian Harrison | BTIG |
| John Tanner | Cantor Fitzgerald & Co. |